Juuli Raivola
Helsinki, 00014, Finland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
ROR1-PI3K/AKT signaling drives adaptive resistance to cell cycle blockade in TP53 mutated ovarian cancer.
Journal: Cell death & disease
Published: August 11, 2025
Molecular and functional profiling of primary normal ovarian cells defines insights into cancer development and drug responses.
Journal: Molecular therapy. Oncology
Published: May 01, 2024
A multiplex single-cell RNA-Seq pharmacotranscriptomics pipeline for drug discovery.
Journal: Nature chemical biology
Published: August 23, 2023
ROR1-STAT3 signaling contributes to ovarian cancer intra-tumor heterogeneity.
Journal: Cell death discovery
Published: January 23, 2023
Cellular thermal shift assay (CETSA) for determining the drug binding affinity using Ba/F3 clones stably expressing receptor pseudokinases.
Journal: Methods in enzymology
Published: May 07, 2022
Multiomics characterization implicates PTK7 in ovarian cancer EMT and cell plasticity and offers strategies for therapeutic intervention.
Journal: Cell death & disease
Published: February 27, 2022
New insights into the molecular mechanisms of ROR1, ROR2, and PTK7 signaling from the proteomics and pharmacological modulation of ROR1 interactome.
Journal: Cellular and molecular life sciences : CMLS
Published: February 13, 2022
Characterization of JAK1 Pseudokinase Domain in Cytokine Signaling.
Journal: Cancers
Published: September 30, 2019
Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases.
Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Published: February 01, 2019
Hyperactivation of Oncogenic JAK3 Mutants Depend on ATP Binding to the Pseudokinase Domain.
Journal: Frontiers in oncology
Published: July 10, 2018
Last Updated: 09/26/2026